Insider Transactions in Q1 2021 at Ironwood Pharmaceuticals Inc (IRWD)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 26
2021
|
Gina Consylman SVP, CFO & Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
56,372
+12.56%
|
-
|
|
Mar 26
2021
|
Thomas A Mccourt Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
96,638
+14.54%
|
-
|
|
Mar 26
2021
|
Jason Rickard SVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
56,372
+13.44%
|
-
|
|
Mar 26
2021
|
Michael Shetzline CMO,SVP,Head-Res&Drug |
BUY
Grant, award, or other acquisition
|
Direct |
38,655
+16.23%
|
-
|
|
Mar 15
2021
|
Catherine Moukheibir |
BUY
Grant, award, or other acquisition
|
Direct |
1,573
+3.11%
|
-
|
|
Mar 15
2021
|
Andrew Dreyfus |
BUY
Grant, award, or other acquisition
|
Direct |
1,460
+1.32%
|
-
|
|
Mar 15
2021
|
Alexander J Denner |
BUY
Grant, award, or other acquisition
|
Direct |
1,235
+3.06%
|
-
|
|
Mar 10
2021
|
Alexander J Denner |
BUY
Open market or private purchase
|
Indirect |
75,000
+0.46%
|
$750,000
$10.54 P/Share
|
|
Mar 08
2021
|
Alexander J Denner |
BUY
Open market or private purchase
|
Indirect |
150,000
+0.91%
|
$1,500,000
$10.3 P/Share
|
|
Mar 05
2021
|
Alexander J Denner |
BUY
Open market or private purchase
|
Indirect |
175,000
+1.07%
|
$1,750,000
$10.01 P/Share
|
|
Mar 04
2021
|
Alexander J Denner |
BUY
Open market or private purchase
|
Indirect |
250,000
+1.54%
|
$2,500,000
$10.0 P/Share
|
|
Mar 03
2021
|
Alexander J Denner |
BUY
Open market or private purchase
|
Indirect |
350,000
+2.18%
|
$3,500,000
$10.02 P/Share
|
|
Mar 02
2021
|
Alexander J Denner |
BUY
Open market or private purchase
|
Indirect |
500,000
+3.15%
|
$4,500,000
$9.56 P/Share
|
|
Mar 01
2021
|
Alexander J Denner |
BUY
Open market or private purchase
|
Indirect |
344,900
+2.26%
|
$3,104,100
$9.6 P/Share
|
|
Feb 26
2021
|
Gina Consylman SVP, CFO & Treasurer |
SELL
Open market or private sale
|
Direct |
18,406
-1.32%
|
$165,654
$9.11 P/Share
|
|
Feb 26
2021
|
Conor Kilroy SVP, GC & Secretary |
SELL
Open market or private sale
|
Direct |
6,989
-1.38%
|
$62,901
$9.11 P/Share
|
|
Feb 26
2021
|
Mark Mallon Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
30,675
-3.1%
|
$276,075
$9.11 P/Share
|
|
Feb 26
2021
|
Thomas A Mccourt Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
14,685
-1.01%
|
$132,165
$9.11 P/Share
|
|
Feb 26
2021
|
Edward P Owens Director |
BUY
Open market or private purchase
|
Direct |
3,000
+1.35%
|
$24,000
$8.9 P/Share
|
|
Feb 26
2021
|
Jason Rickard SVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
13,651
-1.08%
|
$122,859
$9.11 P/Share
|
|
Feb 26
2021
|
Michael Shetzline CMO,SVP,Head-Res&Drug |
SELL
Open market or private sale
|
Direct |
4,439
-1.35%
|
$39,951
$9.11 P/Share
|
|
Feb 26
2021
|
Alexander J Denner |
BUY
Open market or private purchase
|
Indirect |
505,100
+3.36%
|
$4,545,900
$9.2 P/Share
|
|
Feb 25
2021
|
Edward P Owens Director |
BUY
Open market or private purchase
|
Direct |
5,000
+2.26%
|
$45,000
$9.11 P/Share
|
|
Feb 24
2021
|
Edward P Owens Director |
BUY
Open market or private purchase
|
Direct |
7,000
+3.21%
|
$63,000
$9.26 P/Share
|
|
Feb 22
2021
|
Gina Consylman SVP, CFO & Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
84,951
+19.32%
|
-
|
|
Feb 22
2021
|
Thomas A Mccourt Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
145,631
+23.05%
|
-
|
|
Feb 22
2021
|
Jason Rickard SVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
84,951
+20.96%
|
-
|
|
Feb 22
2021
|
Michael Shetzline CMO,SVP,Head-Res&Drug |
BUY
Grant, award, or other acquisition
|
Direct |
58,252
+26.06%
|
-
|